Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase.
The use of superoxide dismutases (SODs) in inflammatory diseases is hampered by their short circulatory half-life. To determine whether a bacterial supply of SOD into the colon might improve an experimental colitis, the effects of oral treatment with live recombinant lactic acid bacteria producing different amounts of SOD and those of colonic infusion of SOD were compared. Wistar rats were fitted with a catheter in the proximal colon through which TNBS was administered to induce colitis. Animals received a continuous intracolonic infusion of bovine SOD (40 U per rat per day) for 4 days after TNBS or were treated orally with live recombinant Lactococcus lactis or Lactobacillus plantarum strains (10 colony-forming units (CFU)/d), producing or not producing SOD, for 4 days before and after TNBS. SOD activity of bacterial extracts was 0, 26, 74, and 624 units/10 CFU for L. plantarum, L. lactis, L. lactis SOD, and L. plantarum SOD, respectively. Four days after TNBS, macroscopic and microscopic damage, myeloperoxidase (MPO) activity, and nitrotyrosine immunostaining were evaluated. TNBS induced macroscopic and microscopic damages, an increase in MPO activity, and intense immunostaining for nitrotyrosine. Macroscopic damage and MPO activity were reduced by bovine SOD. These parameters and microscopic damages also were reduced by L. lactis, L. lactis SOD, and L. plantarum SOD, but not by L. plantarum. Nitrotyrosine immunostaining was attenuated after treatment with the 4 bacterial strains. Although not all of the anti-inflammatory effects could be attributed directly to SOD, our results suggest that SOD-producing lactic acid bacteria open a novel approach in inflammatory bowel disease treatment.
Han
Wei
W
Neurogastroenterology and Nutrition Unit, Institut National de la Recherche Agronomique, Toulouse, France.
Mercenier
Annick
A
Ait-Belgnaoui
Afifa
A
Pavan
Sonia
S
Lamine
Florence
F
van Swam
Iris I
II
Kleerebezem
Michiel
M
Salvador-Cartier
Christel
C
Hisbergues
Michael
M
Bueno
Lionel
L
Theodorou
Vassilia
V
Fioramonti
Jean
J
D000284:Administration, Oral; D000818:Animals; D002417:Cattle; D003092:Colitis / Q000201:enzymology / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D007150:Immunohistochemistry; D007778:Lactobacillus / Q000201:enzymology* / Q000378:metabolism; D008297:Male; D009195:Peroxidase / Q000378:metabolism; D019936:Probiotics / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000008:administration & dosage / Q000096:biosynthesis*; D014302:Trinitrobenzenesulfonic Acid
D014302:Trinitrobenzenesulfonic Acid; D009195:Peroxidase; D013482:Superoxide Dismutase